Venglustat Market Summary

Key Factors Driving Venglustat Growth

1. Positive Phase III results in type 3 Gaucher disease

The Phase III LEAP2MONO study met both primary endpoints and three of four key secondary endpoints. At week 52, venglustat demonstrated statistically significant improvements in neurological symptoms, including ataxia and cognition, compared with enzyme replacement therapy (ERT). The trial randomized 43 patients, with 21 receiving venglustat and 22 receiving ERT. These results provide the main clinical foundation for future adoption.

2. Addressing an important unmet medical need

ERT can manage systemic manifestations of GD3, such as enlarged organs and blood abnormalities, but does not adequately address neurological disease because conventional enzyme therapies do not effectively cross the blood–brain barrier. Venglustat is designed to penetrate the brain and reduce glycosphingolipid accumulation, potentially addressing neurological manifestations that currently lack an approved targeted treatment. This differentiation could support demand among eligible patients if the therapy is approved.

3. Oral administration and treatment convenience

Venglustat is administered once daily by mouth, whereas standard ERT is generally delivered by intravenous infusion every two weeks. In LEAP2MONO, patients had already received ERT for at least three years and achieved treatment goals for systemic disease manifestations before entering the study. An effective oral option could reduce infusion-related inconvenience and broaden treatment choice, although long-term effectiveness and safety will remain important adoption factors.

4. Priority review and breakthrough regulatory designations

Venglustat received FDA Breakthrough Therapy designation in March 2026 for neurological manifestations of GD3. In May 2026, the FDA accepted Sanofi's new drug application for Priority Review, with a target action date of November 25, 2026. Sanofi also reported EU regulatory review for GD3. These milestones could shorten the path to commercialization, although approval is not guaranteed.

5. Potential for favourable tolerability and sustained treatment

In LEAP2MONO, venglustat was generally well tolerated, with no new safety signals reported. Among treated patients, headache occurred in 14.3%, nausea in 14.3%, spleen enlargement in 14.3%, and diarrhoea in 14.3%. These results provide an initial tolerability profile that may support adoption, but the trial's small sample and limited follow-up mean that longer-term safety data will be important.

Venglustat Recent Developments

In March 2026, the US Food and Drug Administration granted venglustat Breakthrough Therapy designation for neurological manifestations of GD3, and in May 2026, the FDA accepted Sanofi’s new drug application for priority review, setting a target decision date of November 25, 2026.

“Venglustat Sales Forecast, and Market Size Analysis – 2034” report provides comprehensive insights of Venglustat for potential indication like Gaucher’s disease type III and Gaucher’s disease in the 7MM. A detailed picture of Venglustat’s existing usage in anticipated entry and performance in potential indications in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2020 –2034 is provided in this report along with a detailed description of the Venglustat for potential indications. The Venglustat market report provides insights about Venglustat’s sales forecast, mechanism of action (MoA), dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of historical and current Venglustat performance, future market assessments inclusive of the Venglustat market forecast analysis for potential indications in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in respective indications. It also provides analysis of Venglustat sales forecasts, along with factors driving its market.

Venglustat Drug Summary

Venglustat is an investigational, orally administered small-molecule drug developed by Sanofi for the treatment of rare lysosomal storage disorders, particularly type 3 Gaucher disease (GD3) and Fabry disease. It acts as a glucosylceramide synthase inhibitor, reducing the production of glucosylceramide, a precursor of more complex glycosphingolipids that can accumulate abnormally in tissues and organs in these disorders. Designed to cross the blood–brain barrier, venglustat aims to reduce substrate accumulation in the central nervous system and potentially address neurological manifestations, including impaired coordination, balance difficulties and cognitive deficits in patients with GD3. The drug is administered orally once daily, offering a convenient alternative to treatments requiring regular intravenous infusions. In February 2026, Sanofi announced positive Phase III LEAP2MONO study results, reporting that venglustat met both primary endpoints and three of four key secondary endpoints in patients aged 12 years and older with GD3, demonstrating improvements in neurological outcomes compared with enzyme replacement therapy. The report provides Venglustat’s sales, growth barriers and drivers, post usage and approvals in multiple indications.

Scope of the Venglustat Market Report

The report provides insights into:

• A comprehensive product overview including the Venglustat MoA, description, dosage and administration, research and development activities in potential indication like Gaucher’s disease type III and Gaucher’s disease.
• Elaborated details on Venglustat regulatory milestones and other development activities have been provided in Venglustat market report.
• The report also highlights Venglustat‘s cost estimates and regional variations, reported and estimated sales performance, research and development activities in potential indications across the United States, Europe, and Japan.
• The Venglustat market report also covers the patents information, generic entry and impact on cost cut.
• The Venglustat market report contains current and forecasted Venglustat sales for potential indications till 2034.
• Comprehensive coverage of the late-stage emerging therapies for respective indications.
• The Venglustat market report also features the SWOT analysis with analyst views for Venglustat in potential indications.

Methodology

The Venglustat market report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Venglustat Analytical Perspective by DelveInsight

• In-depth Venglustat Market Assessment

This Venglustat sales market forecast report provides a detailed market assessment of Venglustat for potential indication like Gaucher’s disease type III and Gaucher’s disease in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides current and forecasted Venglustat sales data uptil 2034.

• Venglustat Clinical Assessment

The Venglustat market report provides the clinical trials information of Venglustat for potential indications covering trial interventions, trial conditions, trial status, start and completion dates.

Venglustat Competitive Landscape

The report provides Insights on competitors and marketed products within the domain, along with a summary of emerging products and their respective launch dates, posing significant competition in the market.

Venglustat Market Potential & Revenue Forecast

• Projected market size for the Venglustat and its key indications
• Estimated Venglustat sales potential (Venglustat peak sales forecasts)
• Venglustat Pricing strategies and reimbursement landscape

Venglustat Competitive Intelligence

• Number of competing drugs in development (pipeline analysis)
• Venglustat Market positioning compared to existing treatments
• Venglustat Strengths & weaknesses relative to competitors

Venglustat Regulatory & Commercial Milestones

• Venglustat Key regulatory approvals & expected launch timelines
• Commercial partnerships, licensing deals, and M&A activity

Venglustat Clinical Differentiation

• Venglustat Efficacy & safety advantages over existing drugs
• Venglustat Unique selling points

Venglustat Market Report Highlights

• In the coming years, the Venglustat market scenario is set to change due to strong adoption, increased prescriptions and broader uptake in multiple immunological indications; which would expand the size of the market.
• The Venglustat companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence Venglustat’s dominance.
• Other emerging products for Gaucher’s disease type III and Gaucher’s disease are expected to give tough market competition to Venglustat and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of Venglustat in potential indications.
• Analyse Venglustat cost, pricing trends and market positioning to support strategic decision-making in the immunology landscape.
• Our in-depth analysis of the forecasted Venglustat sales data uptil 2034 will support the clients in decision-making process regarding their therapeutic portfolio by identifying the overall scenario of Venglustat in potential indications.

Key Questions

• What is the class of therapy, route of administration and mechanism of action of Venglustat? How strong is Venglustat’s clinical and commercial performance?
• What is Venglustat’s clinical trial status in each individual indications such as Gaucher’s disease type III and Gaucher’s disease and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the Venglustat Manufacturers?
• What are the key designations that have been granted to Venglustat for potential indications? How are they going to impact Venglustat’s penetration in various geographies?
• What is the current and forecasted Venglustat market scenario for potential indications? What are the key assumptions behind the forecast?
• What are the current and forecasted sales of Venglustat in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to Venglustat for potential indications?
• Which are the late-stage emerging therapies under development for the treatment of potential indications?
• How cost-effective is Venglustat? What is the duration of therapy and what are the geographical variations in cost per patient?